Skip to main content

The independent medical news service

22-02-2021 | Oncology | News | Article

Novel risk score may enable treatment de-escalation in some prostate cancer patients

The clinical cell-cycle risk score is able to accurately predict metastasis risk in men undergoing dose-escalated radiation therapy, with or without androgen deprivation therapy, for intermediate- to high-risk localized prostate cancer, research suggests.

19-02-2021 | Oncology | News | Article

Dose intensification adds no benefit to post-prostatectomy salvage radiotherapy

Dose intensification does not improve the outcomes of salvage radiotherapy after radical prostatectomy, the SAKK 09/10 investigators have reported at the 2021 Genitourinary Cancers Symposium.

16-02-2021 | Oncology | News | Article

LuPSMA ‘promising alternative’ to cabazitaxel in mCRPC

The radiolabeled small molecule lutetium-177-prostate-specific membrane antigen-617 offers higher activity and better patient-reported outcomes than cabazitaxel in metastatic castration-resistant prostate cancer, research shows.

16-02-2021 | Oncology | News | Article

Immunotherapy–docetaxel combinations show promise in mCRPC

Combining a PD-1 inhibitor with docetaxel could benefit chemotherapy-naïve men with metastatic castration-resistant prostate cancer, suggest results from two early-phase trials.

15-02-2021 | Oncology | News | Article

Radiotherapy activity changed significantly during first COVID-19 peak

The total number of radiotherapy courses delivered in England fell significantly during the first peak of the COVID-19 pandemic but this was accompanied by a rapid increase in the use of hypofractionated regimens, study data show.

14-02-2021 | Oncology | News | Article

Biomarkers of apalutamide response identified in nonmetastatic CRPC

Further analysis of patients with nonmetastatic castration-resistant prostate cancer from the SPARTAN trial has identified molecular biomarkers associated with long-term responses to apalutamide.